Anthrax pipeline review available for purchase from Radiant Insights

Radiant Insights has made the "Anthrax Pipeline Review, H1 2015," which was originally published Jan. 30, available through purchase: the review details therapeutic development for anthrax.

The report details specific information for each candidate that includes its molecule type, its administration route and its mechanisms of action. This report also analyzes candidates on a comparative basis.

The Global Market Direct report includes investigational treatments from around the world. According to the abstract, the full report will allow more efficient decision making and allow for the creation of effective counter strategies for companies that are looking to enter the market with newly established targets and mechanisms of action.

This report consists of a snapshot type view of the global therapeutic market with regard to anthrax treatment, as well as detailed information on drug candidates at various stages of pre-clinical and clinical trials. It also details candidates that were discontinued or otherwise eliminated from consideration, new releases and press statements.

The report contains a list of the companies with leading roles and products in the market and lists both their minor and major projects. It can be purchased at the Radiant Insights webpage; a single license costs $2,000, and a multiple-user license costs $4,000.

Organizations in this Story

Global Market Direct Radiant Insights

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.